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Transient Induction of E-Selectin Expression Following 
TNFa-Based Isolated Limb Perfusion in Melanoma and 
Sarcoma Patients Is Not Tumor Specific
Peet T. G. A. Nooijen, *Alexander M. M. Eggermont, Marcel M. Verbeek, 
ia Schalkwiik, tWim A. Buurman, Robert M. W. de Waal, and Dirk J. Ruit
Department of Pathology, University Hospital Nijmegen, Nijmegen; and Departments of Surgery, :,!Dr. Daniel den
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Summary: Endothelial injury of the tumor microvasculature after isolated limb 
perfusion (ILP) with TNF-a and melphalan is considered to play an important 
role in the pathogenesis of tumor necrosis. It is thought to follow endothelial 
cell activation and subsequent attraction of polymorphonuclear cells (PMNs). 
The observed selectivity for the tumor could be due to preferential overex­
pression of cell-adhesion molecules by the tumor vasculature. We tested this 
proposition by analyzing sequential biopsies from both tumor and normal dis­
tant skin, taken from melanoma and sarcoma patients before ILP and at 30 min 
and 24 h after ILP. Histopathologically confirmed complete response was ob­
served in six of seven melanoma patients, 1-8 months after ILP. By using 
immunohistochemistry on the light- and electron-microscopic level, the ex­
pression patterns of intercellular adhesion molecules-1 (ICAM-1), E-selectin 
(ELAM-1), VCAM-1, and PECAM-1 were examined. In addition, the results 
were compared with the effects on HUVECs (human umbilical vein endothelial 
cells) in vitro of transient exposure of the agents used during ILP. ICAM-1 and 
PECAM-1 were constitutively expressed on vascular endothelial cells, both in 
normal tissues and in the tumor lesions. In biopsies taken 30 min after termi­
nation of the perfusion, a moderate induction of E-selectin expression on the 
vascular endothelium in the tumors and a marked expression on the vascula­
ture in the perfused normal skin were observed. It decreased within 24 h after- 
perfusion in both normal skin and in the tumor. The upregulation of E-selectin 
was accompanied neither by an influx of neutrophils nor by hemorrhagic ne­
crosis. There were no drastic changes in the expression of VCAM-1, ICAM-1, 
or PECAM-1. These findings imply that the upregulation of E-selectin after 
ILP is not restricted to the tumor microvasculature and that, therefore, these 
microvascular events seem not to be the decisive pathomechanism responsible 
for tumor regression. Key Words: Melanoma—Sarcoma—TNF-a—Mel­
phalan—Isolated limb perfusion.
Recombinant human tumor necrosis factor-alpha 
(TNF-a) has potent antitumor activity on human
Received May 24, 1995; accepted December 18, 1995. 
Address correspondence and reprint requests to Dr. P. 
Nooijen, Dept, of Pathology, University Hospital Nijmegen, 
P.O. Box 9101, NL-6500 HB Nijmegen, The Netherlands.
tumor xenografts (1,2) in experimental models. In 
patients, however, the administration of TNF-a is 
hampered by severe systemic side effects. The 
maximum tolerated dose (MTD) (3) amounts only 
350 to 500 jxg/m2, which is at least 10-fold less than 
the efficient dose in animals (4). Isolation perfusion 
of the limbs (ILP) allows the delivery of a high dose
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of TNF-a in a closed compartment with acceptable 
side effects. The protocol used in our center in­
volved a triple-drug regimen, based on the reported 
synergism of TNF-a with melphalan and inter- 
feron-7 (lFN-*y) supplemented with mild hyper­
thermia. In melanoma-in-transit metastasis (stage 
IIIA ,B) a 90% complete response (CR) was ob­
tained compared with —40% CR rate after ILP with 
melphalan alone (5), a regimen cited usually in the 
literature. In irresectable soft-tissue sarcoma, this 
protocol was found to yield 50% CR with 87.5% 
limb salvage, because most tumors became resect­
able (6,7). The Department of Surgery, Dr, Daniel 
den Hoed Cancer Center, Rotterdam, The Nether­
lands, participated in a clinical trial to compare this 
triple-drug regimen with a double-drug regimen 
with TNF-a and melphalan. The double-drug treat­
ment was used in 16 of 17 patients analyzed in this 
study.
Angiographic analysis performed 1 week to 10 
days after ILP showed a dramatic diminishment of 
the tumor-associated vasculature, leaving the nor­
mal small vessels in the limb intact, including small 
vessels in close proximity to the tumor (8). Morpho­
logic and immunohistochemical analysis of biopsies 
of melanoma and soft-tissue sarcoma lesions after 
ILP with the triple-drug regimen suggested that the 
tumor microvasculature is an important target for 
ILP. We and others showed previously that events 
like Von Willebrand factor (VWF) release, platelet 
aggregation, and congestion concentrated on the tu­
mor vasculature, leaving the normal tissues largely 
unaffected (9,10). Moreover, Renard et al. (9) ob­
served E-selectin and VC AM-1 expressed by the 
endothelium followed by a massive polymorphonu­
clear (PMN) accumulation in both sarcoma and 
melanoma lesions after ILP with the triple-drug reg­
imen.
From these findings, the authors suggested a mul­
tistep process of tumor destruction after cytokine 
administration, starting with intratumoral endothe­
lial cell pertubation. This is manifested by overex­
pression of cellular adhesion molecules and fol­
lowed by activation of PMNs, endothelial injury, 
and finally coagulative and hemorrhagic necrosis. A 
similar process has been described in experimental 
models (11). In accordance with this model, the ob­
served specificity of the treatment for tumor tissue 
is a specific upregulation of adhesion molecules in 
the tumor vascular bed. In the non-involved tissues, 
the expression should be largely unaltered. How­
ever, a comparison with unexposed and exposed
normal skin without tumor involvement was not 
made.
In our study, we challenged this proposed selec­
tivity by analyzing sequential biopsies from both 
tumor lesions and normal distant skin from mela­
noma and sarcoma patients with extremity lesions. 
Biopsies were taken before ILP and 30 min and 24 
h after termination of ILP with the double-drug reg­
imen. We determined the expression patterns of the 
cellular adhesion molecules ICAM-1, E-selectin 
(ELAM-1), VCAM-1, and PEC AM-1 (CD31) by im­
munohistochemical analysis on the light-micro­
scopic (LM) and electron-microscopic (EM) level. 
In addition, the results were compared with in vitro 
(12) expression patterns on cultured HUVECs (hu­
man umbilical vein endothelial cells) to be able to 
delineate possible synergistic effects of TNF-a and 
melphalan.
PATIENTS AND METHODS 
Patients and Treatment Schedule
Specifications of the patient characteristics and 
biopsy samples are given in Table 1.
Seventeen patients who entered the ILP protocol 
in the Dr. Daniel den Hoed Cancer Canter, Rotter­
dam, The Netherlands, during the period between 
December 1993 and July 1994, were included in the 
study. Pertinent details about the inclusion criteria, 
types of drugs, and treatment schedule used were 
described earlier (5,6,8). ILP consisted on a 1.5-h 
perfusion with a total amount of 2-4 mg TNF-a in 
combination with melphalan, either 10 mg/L of per­
fused lower limb or 13 mg/L for the upper limb at 
mild hyperthermia (40°C). Sixteen patients were 
treated as follows. At time zero, TNF-a was in­
jected as a bolus into the arterial line. Melphalan 
was administered 30 min later. One patient received
0.2 mg IFN-7 s.c. on 2 subsequent days before ILP. 
The ILP consisted of 0.2 mg IFN-7 , 4 mg TNF-a 
and melphalan, 10 mg/L in the perfused lower limb. 
In all patients, the limb was washed twice with 1 L 
of haemacell and 1 L of 6% dextran 70 (Macrodex; 
Pharmacia, Uppsala, Sweden) at the end of ILP. 
Radioiodinated human serum albumin was added to 
the perfusate to monitor potential leakage of the 
drugs into the systemic circulation. Perioperatively, 
dopamine was administered at 2 jxg/kg/min by con­
tinuous infusion, usually for several hours up to 48 
h. Fluid loading was applied before releasing the 
tourniquet at the end of the washing period.
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TABLE L Patient characteristics and specification of biopsy samples
Patient Diagnosis
Normal skin 
(Number of biopsies)
Tumor 
(Number of biopsies)
30 min 
Before ILP after ILP
24 h 
after ILP Before ILP
30 min 
after ILP
24 h 
after ILP
I" Melanoma 2 2 2 3 3 5
21 Melanoma 0 2 4 I
3" Melanoma 2 2 *0 "î 3
4° Melanoma 2 *> 2 2 2 2
5“ Melanoma 1 1 - I 1 U I- .
6 Melanoma 2 2 2 2 ——
7 Melanoma — - - 2 2
8 Clear-cell sarcoma 1 i 1 —- - I
9 Clear-cell sarcoma 2 2 — 2 2 -
10 Clear-cell sarcoma 2 2 - 1 1 -
11 Malignant fibrous histiocytoma 1 2 - - - —
12 Synoviosarcoma 2 2 - - —
13 Myxoid liposarcoma - 2 - - 6 —
14 Synoviosarcoma i4* - 2 2 -—
15 Hemangiopericytoma 2 2 - 2 2 -—
16 Epithcloid cell sarcoma 2 2 - 2 2 —
17" Lymphangiosarcoma 2 2 2 2 2 2
ILP, isolated limb perfusion.
“ Material for immunoelectron microscopic analysis also was taken.
Oral informed consent to take sequential biopsies 
from normal skin of the involved extremity and the 
tumor lesions was obtained from the patients. Ex­
cision biopsy of normal skin was taken at least 15 
cm outside the melanoma or sarcoma lesion in areas 
without macroscopic signs of disease. In total, 137 
biopsies from 17 patients (excision and punch biop­
sies from melanoma patients and Trucut needle bi­
opsies from sarcoma patients). From six patients 
samples from both normal skin and tumor tissue 
before, 30 min after, and 24 h after termination of 
ILP were taken and prepared for immunoelectron 
microscopy (IEM).
The responses to the ILP treatment— CR, partial 
response (PR), no change (NC), and progressive 
disease (PD)— were assessed by standardized crite­
ria (13). In the melanoma patients, the response was 
histologically confirmed by a biopsy 1 to 8 months 
after perfusion. In sarcoma patients who underwent 
a resection or residual mass, extensive histologic 
examination of the resected specimen was per­
formed. Six of seven melanoma patients had a CR 
to the treatment, whereas one had a PR. All sar­
coma patients showed tumor softening and necro­
sis. One sarcoma patient had a CR with 100% ne­
crosis, whereas nine of 10 had a PR.
Immunohistochemistry
Cry os tat sections (4 jxm) of normal skin, mela­
noma, and sarcoma lesions after ILP were air-dried
overnight at room temperature (RT), fixed in ace­
tone for 10 min, again air-dried and incubated with 
the primary antibody for 60 min. The following an­
tibodies were used: PAL-E, recognizing endothelial 
cells (14,15) (our laboratory, undiluted superna­
tant); KH 58.01 POS, recognizing RaHuVWF (Von 
Willebrand factor; 1:400); CL203, recognizing 
ICAM-1 (16) (CD54 1:800; kindly provided by Dr. 
S. Ferrone); ENA-1, recognizing E-selectin (17), 
(CD62e 1:20; kindly provided by Dr. W , Buurman); 
1G11, recognizing VCAM-1 (18) (CD106 1:20; Im- 
munotech); BBA7, recognizing PECAM (19) (CD31 
1:5000; British Biotechnology). Subsequently, sec­
tions were incubated for 30 min with peroxidase- 
labeled rabbit anti-mouse antibodies (Dako, 1:100) or 
with the ABC detection kit, according to the manu­
facturer’s description (Vector, Burlingame, CA, 
U.S.A.). Each incubation was followed by extensive 
washing in phosphate-buffered saline (PBS). Peroxi­
dase activity was visualized by incubation with the 
chromogen 3-amino-9-ethylcarbazole for 10 min. Sec­
tions were counterstained with Harris hematoxylin 
and mounted with Kaiser’s glycerin* The whole pro­
cedure was performed at RT. Secondary antibodies 
were tested for cross-reactivity by omitting the pri­
mary antibody, and positive controls were performed 
by staining frozen sections of skin affected with acute 
or chronic inflammation.
The staining intensity of the endothelium and tu­
mor cells was scored as negative (- ), weak (±),
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dull (+), moderate (+ +), or marked (+ + +). The 
proportion of vascular cross-sections stained for ei­
ther antibody was estimated as a percentage of the 
total number of PAL-E-positive vascular cross- 
sections in the slide and scored in one of the fol­
lowing categories: 0-5%, 6-25%, 26-50%, 51-75%, 
and 76-100%. All slides were read by two indepen­
dent observers. In case of disagreement, consensus 
could be reached by joint reexamination.
Enzymehistochemical detection of chloroacetate- 
esterase for the localization of neutrophils and mast 
cells was performed by a standard method (20).
Immunoelectron Microscopy
A pre-embedding immunoperoxidase technique 
was used to demonstrate the precise cellular local­
ization and subcellular distribution of the staining 
with the mAbs. Tissue specimens from normal skin 
and tumor were fixed for 4 h at RT in freshly pre­
pared 2% paraformaldehyde in Sorensen’s phos­
phate buffer (pH 7.4). After washing for 1 h in PBS 
at RT and for 45-60 min in 2.3 M sucrose solution, 
the tissue was snap-frozen in liquid nitrogen and 
stored at — 196°C. Cryosections (30 jxm) were 
washed in PBS at RT for 1.5 h. These sections were 
incubated free-floating overnight with the primary 
antibody at 4°C diluted in a PBG buffer (PBS +
0.5% BSA H- 0.1% gelatin, pH 7.4) by using a rotary 
shaker. After washing in PBS for 1.5 h, the sections 
were incubated with a peroxidase-conjugated sec­
ondary antibody at the appropriate dilution in PGB 
for 1.5 h at RT.
Control sections were incubated with the second­
ary antibody alone. After extensive washing in PBS 
for 1.5 h at RT, the sections were incubated in a 5 
mg/ml diaminobenzidine (DAB; Sigma, St. Louis, 
MO, U.S.A.) solution in PBS, containing 3 mg/ml 
ammonium-nickel-sulfate-hexahydrate. The sec­
tions were then developed for 8-10 min in the same 
solution containing 0 .01% H20 2. The reaction was 
terminated by rinsing with tap water. Sections were 
postfixed with 1% osmium tetroxide for 5 min at 
RT, dehydrated, and embedded in Epon 812. Sec­
tions (1 fim) were stained with toluidine blue and 
examined light microscopically. Ultrathin sections 
were contrasted for 1 minute with 3% uranylacetate 
and examined on a JEOL 1200 EX/II electron mi­
croscope (Tokyo, Japan) at 40 kV.
ELISA
An enzyme-linked immunosorbent assay (ELISA) 
on cultured HUVECs was performed to detect
E-selectin, ICAM-1, or VCAM-1 expression, as de­
scribed previously (21). HUVECs were seeded in 
gelatin-coated 96-well microtiter plates (Costar, 
Cambridge, MA, U.S.A.) at a density of 2 x 104 
cells/well and allowed to grow to confluence in the 
appropriate medium for 3 days. Subsequently the 
cells were incubated with 10 jxg/ml TNF-a (a gift 
from Boehringer Ingelheim) or melphalan, 40 jjug/ 
ml, or perfusate, obtained during ILP and contain­
ing the actually used dose of TNF-a and melphalan, 
for 1 h. After extensive washing, cells were incu­
bated in the culture medium again. After various 
intervals, cells were washed with EMEM (Eagle’s 
minimal essential medium, Biowhittaker, Belgium) 
and fixed with 0.025% glutaraldehyde in PBS for 10 
min at RT. The wells were incubated with 1% gel­
atin in PBS for 30 min at 37°C to prevent nonspe­
cific binding of antibodies. After washing with PBS, 
the wells were successively incubated for 30 min at 
37°C with the primary antibodies and with peroxi- 
dase-labeled rabbit anti-mouse immunoglobulin (di­
luted 1:500 in PBS, containing 1% gelatin). Enzyme 
substrate was then added (8 mg/ml 5-aminosalicylic 
acid; Sigma) in 50 mM phosphate buffer (pH 6.0) 
with 0.025% H20 2. Color development was mea­
sured after 30 min by reading the optical density 
(OD) at 450 nm in a Titertek ELISA  plate reader 
(Flow Laboratories, Irvine, Scotland).
RESULTS
Immunohistochemical Analysis
The results in this section are presented per indi­
vidual adhesion molecule; staining intensity is ex­
pressed as described in the Materials and Methods 
section, followed by the percentage of positively 
stained blood vessels (100%, all PAL-E-stained 
vessels).
PEC AM-1 Expression
In frozen sections of normal skin before ILP, 
marked PECAM-1 expression was detectable on 
the endothelial cells of venules, arterioles, and large 
vessels (+ + + , 76-100%). The PAL-E-negative 
lymphatic endothelium also was positively stained 
with dull intensity ( + ). Melanoma and sarcoma 
cells did not stain. Vascular endothelial cells in ei­
ther the melanoma or sarcoma lesions were mark­
edly stained (H—I—I-, 76-100%). The staining pat­
terns in normal skin and in the tumor lesions were
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not altered, both at 30 min and at 24 h after ILP 
(Figs. 1 and 3C). The melanoma and sarcoma cells 
remained unstained. IEM  showed that the majority 
of the blood vessels were intensely labeled by the 
anti-PEC AM-1 antibody at the luminal and ablumi- 
nal side of the endothelium. Parts of the pinocytotic 
vesicles, mainly at the luminal side, were positively 
stained. No other part of the microvasculature 
showed PECAM-1 positivity (Fig. 3D).
ICAM-1 Expression
Before ILP , ICAM-1 was constitutively ex­
pressed in frozen sections of normal skin on vascu­
lar endothelial cells (H-, 51-75%) and on dermal 
dendritic cells with dull staining intensity ( + ). The 
tumor vascular endothelium stained (+ , 51-75%) in 
the melanoma and sarcoma lesions before ILP. In 
all melanoma lesions, tumor cells and stroma cells 
( +, 51-75%) were stained. Thirty minutes after ter­
mination of ILP, the staining intensity on the endo­
thelial and dermal dendritic cells increased (from + 
to + +), both in normal skin and in the melanoma 
and sarcoma lesions. The percentage of the vessels 
stained remained unchanged (Fig. 5E). The staining 
of tumor cells and stromal cells remained un­
changed. At 24 h after ILP, the staining intensity 
was decreased to the level observed before ILP (+, 
51-75%), both in normal skin and in the tumor le­
sions (Figs. 1 and 3E). IEM  analysis showed a 
marked ICAM-1 staining of the luminal side of en­
dothelial cells. Sparsely pinocytotic vesicles were 
stained. No other part of the micro vascular wall 
showed ICAM-1 staining (Fig. 3F).
E-Selectin Expression
In normal skin before ILP, the external sheath of 
the hair follicles markedly stained (+ + +), in con­
trast to the unstained vascular endothelial cells. 
Whether this staining could be considered specific 
or nonspecific was not known. Melanoma and sar­
coma cells did not stain. The tumor vascular endo­
thelium showed a weak staining (±, 5%) at the pe­
riphery of the tumor in two (of seven) melanomas 
and two (of 10) sarcoma lesions; in the remaining 
biopsies, the vascular endothelium did not stain. 
However, 30 min after termination of ILP, a high 
percentage (76-100%) of the vascular endothelium 
in normal distant skin and in skin adjacent to mel­
anoma lesions stained with moderate to marked in­
tensity (+ +/+ + +) (Figs. 1, 2A and B, 3A, and 6A
Tumor
Before ILP
Skin
PECAM
I CAM
ELAM
VCAM
100 75 50 2 5 0 26 50 75 1 00 
P ercen tage  o f th e  e n d o th e liu m  s ta in e d
Tumor ^  m inutes after IL P
PECAM
ICAM
ELAM
VCAM
100 75 50 25 0 25 B0 75 100 
P e rc e n ta g e  o f th e  e n d o th e liu m  s ta in e d
Tumor 2 4  h o u r s  a f te r  I L P  Skin
PECAM
ICAM
ELAM
VCAM
100 75 60 26 0 25 50 75 100 
P e rce n ta g e  o f  th e  e n d o th e liu m  s ta in e d
FIG. 1. Staining patterns of endothelial cell adhesion molecules 
in normal adjacent skin and tumor tissue. Right bars, normal 
skin; left bars, tumor tissue. The length of each bar represents 
the percentage of vascular cross-sections stained, estimated as a 
percentage of the total number of PAL-E positive vascular cross- 
sections. The pattern of each bar corresponds to the intensity as 
follows: no shading, ± to + ; Light shading, + + ; and dark shad­
ing, + + +.
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FIG. 4. The effects of a pulse of TNF-a (A, D, G), melphalan (B, E, H), and perfusate (C, F, I) on the expression of E-selectin (A, 
B, C), ICAM-1 (D, E, F), and VCAM-1 (G, H, I) by cultured HUVECs. The vertical axis represents arbitrary extinction units, read at 
450 nm. One of four representative experiments is shown.
Melanoma and sarcoma cells did not stain. Thirty 
minutes after termination of ILP, the staining pat­
tern was unchanged both in normal skin and in the 
melanoma and sarcoma lesions (Fig. 1). By IEM 
analysis, we did not observe VCAM-1 staining of 
the cutaneous micro vasculature.
In Vitro Experiments
Although the use of cultured cells may have lim­
ited value in predicting or explaining in vivo mech­
anisms, we made an attempt to delineate possible 
synergistic effects of TNF-a and melphalan on the 
expression patterns of E-selectin, ICAM-1, and 
VCAM-1 on cultured HUVECs. To mimic the 
clinical situation most closely, the exposure of 
HUVECs to TNF-a, melphalan, and perfusate was 
limited to 1 h. The drug regimen used in vitro was 
similar to that used in vivo, which is based on the
reported synergism of TNF-a with chemotherapy. 
Exposure of HUVECs to a pulse of TNF-a, 10 *xg/ 
ml for 1 h, resulted in a marked upregulation of 
E-selectin and ICAM-1 expression (Fig. 4A and D). 
E-selectin expression reached a maximum after 4 h 
and decreased within 24 h. ICAM-1 expression 
reached a maximum after 24 h. The VCAM-1 ex­
pression did not differ significantly from control 
levels (Fig. 4G).
Exposure of HUVECs to a pulse of melphalan, 40 
jxg for 1 h, did not result in a significant upregula­
tion of E-selectin and VCAM-1 (Fig. 4B and H). 
Repeated experiments did not reveal a significant 
pattern of induction of ICAM-1 expression as com­
pared with control levels, but a trend toward an 
increased expression after 24 h could be observed 
(Fig. 4E).
Exposure of HUVECs to perfusate (with 4 jxg/ml 
TNF-a and 10 jjig/ml melphalan) for 1 h resulted in
J  Immunother, Vol. 19, No. 1, 1996
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dermal injections of cytokines in baboons (20,33). 
In baboons, intradermal injections of TNF-a (or 
TNF-a with IFN-7 ) induced a rapid induction of 
E-selectin expression on the vascular endothelium 
(which correlated with neutrophil extravasation) 
and a delayed increase in 1CAM-1 (which correlated 
with the onset of lymphocyte accumulation). In hu­
mans, diseased tissues have been examined for the 
expression of cell-adhesion molecules. E-selectin 
was present on vascular endothelial cells in the 
acute inflamed skin (19,34) and on endothelial cells 
in several tumors characterized by high local con­
centrations of cytokines (especially TNF-a; 35). In­
tradermal injections of TNF-a indicate that TNF-a 
is pro-inflammatory in human skin and modulates 
cutaneous adhesion molecule expression (36).
A  pharmacologically high dose of TNF-a is given 
in combination with melphalan during the ILP, a 
regimen that is likely to yield a different pathophys­
iologic response than is observed during an inflam­
matory reaction. Renard et al. (7) investigated bi­
opsies of 27 patients (melanoma and sarcoma) 
treated with high doses of TNF-a, IFN-7 , and mel­
phalan. The authors suggested that the clinically ev­
ident preferential sensitivity of the tumor vascula­
ture for the triple-combination therapy could be 
based on a cascade starting with a selective over­
expression of cellular-adhesion molecules by the tu­
mor vascular endothelium. However, a comparison 
with unexposed and exposed skin from the same 
patients was not available.
In our study, we sequentially surveyed skin tis­
sue with and without tumor lesions before and after 
ILP and TNF-a and melphalan, without IFN-7 . We 
found a marked immunostaining for E-selectin on 
the vascular endothelium 30 min after termination 
of perfusion in both normal skin and the melanoma 
and sarcoma lesions. The percentage of vascular 
endothelium that became positive for E-selectin 
was even higher in normal skin than in the tumors 
(both melanoma and sarcoma). Therefore, a selec­
tive overexpression of adhesion molecules on the 
tumor vasculature after perfusion cannot be the 
mechanism behind the antitumor effect. It is our 
opinion that the limited material in the “ normal 
skin” group in the study of Renard et al. (9) may 
explain the different conclusion reached by these 
authors.
The rapid increase of E-selectin expression after 
ILP in both tumor and normal vessels makes this 
adhesion molecule not a useful marker to discrimi­
nate between “ normal” and “ tumor” vessels, but it
may mark those vessels that were actually per­
fused. In this respect, it is notable that in both mel­
anoma and sarcoma lesions expression of E-selectin 
was confined to the vascular endothelium in the pe­
riphery of the tumor. We therefore speculate that 
the agents used have not or have poorly reached the 
tumor center. According to Jain (37,38), aberrant 
branching and twisting of the vasculature and ab­
normal high pressure in the interstitial matrix of the 
tumor center may have contributed to this uneven 
distribution of the drugs.
We were surprised to find leukostasis and an in­
flammatory infiltrate in the biopsies of only one pa­
tient with melanoma. Expression of an inducible 
cell-adhesion molecule like E-selectin is apparently 
not necessarily followed by leukocyte adhesion. 
This phenomenon may be explained by assuming 
that the adhesion properties of leukocytes to E-se- 
lectin are also dependent on its ligand (39), which 
may be functionally inactive, as stated by Pober and 
Cotran (31). Alternatively, inhibitory factors may 
be present. For example, IL -8 renders neutrophils 
less able to interact with E-selectin (40), and in­
creased levels of this cytokine (and IL-6) have been 
demonstrated in the ILP circuit during treatment 
(41). Soluble adhesion molecules, shed from the cell 
surface, may counteract leukocyte accumulation as 
well (42). The presence of these factors was not 
analyzed in our material. For an optimal monitoring 
of the duration of E-selectin expression and infil­
trate formation in the sarcoma patients, the number 
of biopsies has to be extended at least to 8-12 h 
after perfusion. Obviously, this is limited by clinical 
and ethical restrictions based on the increased in­
fection risk of taking needle biopsies.
The response rate in melanoma-in-transit me­
tastasis after double-drug ILP (CR in six of seven 
patients) was comparable with results after triple­
combination therapy. In contrast to earlier reports, 
we did not find hemorrhagic and coagulative necro­
sis in the melanoma lesions within 24 h after perfu­
sion. Sampling bias was minimized by taking mul­
tiple biopsies per period per patient. In case of a 
complete response, biopsies 8 weeks after ILP re­
vealed dermal fibrosis with infiltration by macro­
phages and lymphocytes. (Biopsies that were taken 
8-10 weeks after perfusion are not included in Table
1. These biopsies were formalin-fixed and embed­
ded in paraffin to verify the response to treatment 
but were not available for immunohistochemistry.)
The presence of regression of melanoma in the 
absence of granulocytes and hemorrhagic or coag-
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ulative necrosis may imply that the proposed cas­
cade, starting with E-selectin expression, is not the 
decisive mechanism resulting in regression of the 
tumor observed in our melanoma patients. The ob­
served regression of the melanoma lesions 8-10 
weeks after perfusion may still be immune medi­
ated, a possibility that needs future investigations. 
The variability in response to ILP and the occur­
rence of necrosis may be a result of difference in the 
extent of (neo)vascularization and tumor volume. 
All the melanoma metastases we analyzed had a 
diameter =s0.5 cm (43,44). Obviously, the sensitiv­
ity of the tumor for ILP is influenced by more fac­
tors than the mere expression of adhesion mole­
cules. For instance, differences in the interstitial 
environment and in immunoreactivity between tu­
mor and normal tissues may play a role. Further 
investigations are therefore necessary to explain the 
exact nature of this selective response.
Acknowledgment: This study was supported by a grant 
from the Dutch Cancer Society (NKB 93-659). We thank 
F. J. R. Rietveld for his expert technical assistance with 
IEM.
REFERENCES
1. Balkwill FR, Lee A, Aldam G, et al. Human tumor xe­
nografts treated with recombinant human tumor necrosis 
factor alone or in combination with interferons. Cancer Res 
1986;46:3990-3.
2. Haranaka K, Satomi N, Sakurai A. Antitumor activity of 
murine tumor necrosis factor (TNF) against transplanted 
murine tumors and heterotranspianted human tumors in 
nude mice. I  fit J  Cancer 1984;34(2):263-7.
3. Spriggs DR, Sherman ML, Michie H, et al. Recombinant 
human tumor necrosis factor administered as a 24 h intrave­
nous infusion: a phase I and pharmacologic study. J Natl 
Cancer Inst 1988;80(13): 1039-44.
4. Asher A, Mule JJ, Reichert CM, Shilone E, Rosenberg SA. 
Studies on the anti-tumor efficacy of systemically adminis­
tered recombinant tumor necrosis factor against several mu­
rine tumors in vivo. J  Immunol 1987; 138(3)*.963-74.
5. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. 
Isolated perfusion of the limb with high-dose tumour necro­
sis factor-alpha (TNF-a), interferon-gamma (IFN-'y) and 
melphalan for melanoma stage III: results of a multi-centre 
pilot study. Melanoma Res 1994;4(suppl l):21—6.
6. Lejeune FJ, Liénard D, Eggermont AMM, et al. Rationale 
for using TNF alpha and chemotherapy in regional therapy 
of melanoma. J Cell Biochem 1994;56( 1):52—61.
7. Eggermont AMM, Liénard D, Schraffordt Koops H, Kroon 
BBR, Rosenhaimer F, Lejeune FJ. Limb salvage by isolated 
limb perfusion of the limbs with high dose TNF-a, gamma 
interferon and melphalan for stage III melanoma and irre- 
sectable soft tissue sarcomas of the extremities. In: Contri­
butions to oncology. Karger, in press.
8. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune 
FJ. High-dose recombinant tumor necrosis factor-alpha in 
combination with interferon gamma and melphalan in isola­
tion perfusion of the limbs for melanoma and sarcoma. J  Clin 
Oncol 1992; 10(l):52-60.
9. Renard N, Lienard D, Lespagnard L, Eggermont AMM, 
Heimann R, Lejeune FJ. Early endothelium activation and 
polymorphonuclear cell invasion precede specific necrosis 
of human melanoma and sarcoma treated by intravascular 
high dose tumor necrosis factor-alpha (rTNFa). In tJ Cancer 
1994;57(5):656—63.
10. Renard N, Nooijen PTGA, Schalkwijk L, et al. VWF release 
and platelet aggregation in human melanoma after perfusion 
with TNFa. J Pathol 1995;176:279-87.
11. Pal 1 ad i no MA Jr, Shalaby MR, Kramer SM, et al. Charac­
terization of the anti-tumour activities of human tumour ne­
crosis factor-alpha and the comparison with other cytokines: 
induction of tumours-specific immunity. J Immunol 1987; 
138:4023-32.
12. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin 
and intercellular adhesion molecule-1 are released by acti­
vated human endothelial cells in vitro. Immunology 1992;77 
(4):543-9.
13. World Health Organization. WHO handbook for reporting 
results of cancer treatment. WHO offset Publ No 48. 
Geneva: WHO, 1979.
14. Ruiter DJ, Schlingemann RO, Rietveld FJR, et al. Monoclo­
nal antibody defined human endothelial antigens as vascular 
markers. J Invest Dermatol 1989;93:224-32.
15. Schlingemann RO, Dingjan GM, Emeis JJ, et al. Monoclonal 
antibody PAL-E specific for endothelium. Lab Invest 1985; 
52:71-6.
16. Kageshita T, Yoshii A, Kimura T, et al. Clinical relevance of 
ICAM-1 expression in primary lesions and serum of patients 
with malignant melanoma. Cancer Res 1993 ;53(20):4927—32.
17. Leeuwenberg JEM, Jeunhomme TMAA, Buurman WA. 
Role of ELAM-1 in adhesion of monocytes to activated en­
dothelial cells. Scand J  Immunol 1992;35:335-41.
18. Weber C, Erl W, Pietsch A, Strobel M, Zicgler-Heibrock 
HW, Weber PC. Antioxidants inhibit monocyte adhesion by 
suppressing nuclear factor-kappa B mobilization and induc­
tion of vascular adhesion molecule-1 in endothelial cells 
stimulated to generate radicals. Arteriosclcr Thromb 1994; 
14(l0):1665-73.
19. Simmonds D, Needham L. Vascular endothelium: interac­
tions with circulating cells. Gordon: Elsevier Science Pub­
lishers, 1991.
20. Bancroft DJ, Stevens A, eds. Theory and practice of histo­
logical techniques. New York: Churchill Livingstone, 
1986:402-3.
21. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, 
Ruiter DJ, De Waal RMW. Accumulation of intercellular 
adhesion molecule-1 in senile plaques in brain tissue of pa­
tients with Alzheimer’s disease. Am J Pathol 1994; 144(1): 
104-16.
22. Von Asmuth EJU, Smeets EF, Ginsel LA, Onderwater JJM, 
Leeuwenberg JFM, Buurman WA. Evidence for endocyto- 
sis of E-selectin in human endothelial cells. Eur J  Immunol 
1992 ;22(10):2519-26.
23. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gim- 
brone MA Jr. Identification of an inducible endothelial- 
leucocyte adhesion molecule. Proc Natl Acad Sci USA 
1987;84(24):9238^t2.
24. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. En­
dothelial leucocyte adhesion molecule I: an inducible recep­
tor for neutrophils related to complement regulatory pro­
teins and lectins. Science 1989;243(4895):1160-5.
25. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyi S, 
Hemler ME. VCAM-1 on activated endothelium interacts 
with the leucocyte integrin VLA-4 at a site distinct from the 
VLA-4/fibronectin binding site, Cell 1990;60(4):577-84.
26. Westphal JR, De Waal RMW. The role of adhesion mole­
J Immunother, Vol. 19, No. 1, 1996
44 P. 'L G. A. NO01 JEN ET AL.
cules in the endothelial cell accessory function. Mol Biol 
Rep 1992; 17(1):47—59.
27. Silber A, Newman W, Reimann KA, Hendricks E, Walsh D, 
Ringler DJ. Kinetic expression of endothelial adhesion mol­
ecules and relationship to leukocyte recruitment in the two 
cutaneous models of inflammation. Lab Invest 1994;70(2): 
163-75.
28. Cotran RS, Gimbrone MA Jr, Bevilacqua MP, Mendrick 
DL, Pober JS. Induction and detection of human endothelial 
activation antigen in vivo. J Exp Med 1986; 164(2):661—6.
29. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and 
interferon gamma induce distinct patterns of endothelial ac­
tivation and associated leucocyte accumulation in skin of 
Papio Anubis, Am J  Pathol 1989; 135(1): 121-33.
30. Munro JM, Pober JS, Cotran RS. Recruitment of neutrophils 
in local endotoxin response: association with de novo endo­
thelial expression of endothelial leucocyte adhesion mole­
cule-1. Lab Invest 1991;64:295-9.
31. Pober JS, Cotran RS. What can be learned from the expres­
sion of adhesion molecules in tissues? [Editorial]. Lab Invest 
1991;64:301-5.
32. Waldorf HA, Walsh LJ, Schechter NM, Murphy GF. Early 
cellular events in evolving cutaneous delayed hypersensitiv­
ity in human. Am J  Pathol 1991;138(2):477-86.
33. Redl H, Dinges HP, Buurman WA, et al. Expression of en­
dothelial leucocyte adhesion molecule-1 in septic but not 
traumatic/hypovolemic shock in the baboon. Am J Pathol 
1991; 139(2) ;461-6.
34. Cotran RS, Pober JS. Endothelial activation: its roie in in­
flammatory and immune reactions. In: Simionescu N, Simt- 
onescu M, eds. Endothelial cell biology. New York: Ple­
num, 1988:335.
35. Ruco LP, Pomponi D, Pigott R, et al. Cytokine production
(IL-la, IL-lp and TNF) and endothelial cell activation 
(ELAM-1 and HLA-DR) in reactive lymphodenitis, Hodg­
kin’s disease and in non-Hodgkin’s lymphomas: an immu- 
nohistochemical study. Am J  Pathol 1990;137(5): 1163-71.
36. Groves RW, Allen MH, Ross EL, Barker JN, Macdonald 
DM. Tumour necrosis factor alpha is pro-inflammatory in 
normal human skin and modulates cutaneous adhesion mol­
ecule expression. Br J Dermatol 1995;132(3):345-52.
37. Jain RK. Transport of molecules across tumor vasculature. 
Cancer Metastasis Rev 1987;6(4):559-93.
38. Jain RK. Transport of molecules in the tumor interstitium: a 
review. Cancer Res 1987;47( 12):3039—51.
39. Smeets EF, De Vries T, Leeuwenberg JFM, Van den Ei- 
jnden DH, Buurman WA, Neefjes JJ. Phosphorylation of 
surface E-selectin and the effect of soluble ligand (sialyl 
Lewis) on the half-life of E-selectin. Eur J Immunol 1993; 
23:147-51.
40. Gimbrone MA Jr, Obin MS, Brock AF, et al. Endothelial 
interleukin-8: a novel inhibitor of leucocyte-endothelial in­
teractions. Science 1989 ;246(4937): 1601-3.
41. Quinn TD, Polk HC Jr, Edwards MJ. Hyperthermic isolated 
limb perfusion increases circulating levels of inflammatory 
cytokines. Cancer Immunol Immunother 1995;40:272-5.
42. Biann AD, McCollum CN. Circulating endothelial cell/ 
leucocyte adhesion molecules in arteriosclerosis. Thromb 
Haemost 1994;72(1): 151-4.
43. Denekamp J, Hill SA, Hobson B. Vascular occlusion and 
tumour cell death. Eur J Cancer Clin Oncol 1983; 19(2): 
271-5.
44. Peterson HI, ed. Tumor blood circulation; angiogenesis, 
vascular morphology and blood flow of experimental and 
human tumors. Florida: CRC Press, 1979:1-229.
J  Immunother, Vol. 19, Mo, 1, 1996
